Year: 2017
Type: article
Abstract: One potential therapeutic strategy for Alzheimer's disease (AD) is to use antibodies that bind to small soluble protein aggregates to reduce their toxic effects. However, these therapies are rarely tested in human CSF before clinical trials because of the lack of sensitive methods that enable the measurement of aggregate-induced toxicity at low concentrations. We have developed highly sensitive single vesicle and single-cell-based assays that detect the Ca 2+ influx caused by the CSF of individuals affected with AD and healthy controls, and we have found comparable effects for both types of samples. We also show that an extracellular chaperone clusterin; a nanobody specific to the amyloid-β peptide (Aβ); and bapineuzumab, a humanized monoclonal antibody raised against Aβ, could all reduce the Ca 2+ influx caused by synthetic Aβ oligomers but are less effective in CSF. These assays could be used to characterize potential therapeutic agents in CSF before clinical trials.
Source: Cell Reports
Authors: Anna Drews, Suman De, Patrick Flagmeier, David C. Wirthensohn, Wei-Hsin Chen, Daniel R. Whiten, Margarida Rodrigues, Cécile Vincke, Serge Muyldermans, Ross W. Paterson, Catherine F. Slattery, Nick C. Fox, Jonathan M. Schott, Henrik Zetterberg, Christopher M. Dobson, Sonia Gandhi, David Klenerman
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $5,887
Funders: AstraZeneca, Wellcome Trust, National Institute for Health and Care Research, Royal Society, University College London, Boehringer Ingelheim Fonds, Alzheimer’s Research UK, Studienstiftung des Deutschen Volkes, Vetenskapsrådet, University College London Hospitals NHS Foundation Trust, Directorate for Biological Sciences, Medical Research Council, Engineering and Physical Sciences Research Council, Biotechnology and Biological Sciences Research Council, UCLH Biomedical Research Centre, H2020 European Research Council
Awards: G1170993257, Development of High-Speed SICM for Biological Applications, G388146651, G5111822078, Next generation live super-resolution microscopy: development and application at the Cambridge Advanced Imaging Centre, Characterising protein oligomers and their role in neurodegenerative disease in humans, G6484388742, G6508665183, G7860843858, Mechanisms of neurotoxicity of amyloid aggregates, The role of alpha-synuclein misfolding in Parkinson's disease.
OpenAlex ID: W2772111047
